Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glioblastoma
100%
Tumor Treating Fields
100%
Dermatological Adverse Effects
100%
Skin Adverse Events
36%
Survival Benefit
18%
Duration of Use
18%
Tumor Bed
18%
Adverse Event Management
18%
Newly Diagnosed Glioblastoma
18%
Healthcare Professionals
9%
Therapeutic Implications
9%
Clinical Trials
9%
Adverse Events
9%
Overall Survival
9%
Temozolomide
9%
Recurrent Glioblastoma
9%
Safety Profile
9%
Minimal Impact
9%
Quality of Life
9%
Prevention Strategies
9%
Clinical Experience
9%
Skin Reactions
9%
Antibiotics
9%
Treatment Outcome
9%
Early Identification
9%
Clinical Phenotype
9%
Recommended Treatment
9%
Field Treatment
9%
Rash
9%
Pruritus
9%
Symptom Severity
9%
Adherence to Therapy
9%
Mesothelioma
9%
Prophylactic Treatment
9%
Scalp
9%
Contact Dermatitis
9%
Ulcer
9%
Implications for Practice
9%
Antimitotic
9%
Temozolomide Chemotherapy
9%
Enhanced Efficacy
9%
Skin Erosion
9%
Skin Care
9%
Hyperhidrosis
9%
Field Use
9%
Irritant
9%
Transducer Array
9%
Daily Use
9%
Xerosis
9%
Lotion
9%
Petroleum-based
9%
Antiperspirant
9%
Skin Barrier Film
9%
Ointment
9%
Electrical Impedance
9%
Water-based
9%
Alternating Electric Field
9%
Moisturizer
9%
Well Tolerated
9%
Management Strategies
9%
Efficacy Outcomes
9%
Treatment-related Adverse Events
9%
Topical Corticosteroids
9%
Medicine and Dentistry
Glioblastoma
100%
Dermatological Agent
100%
Tumor Treating Fields
100%
Adverse Event
100%
Neoplasm
18%
Temozolomide
18%
Infection
9%
Clinical Trial
9%
Overall Survival
9%
Patient Compliance
9%
Quality of Life
9%
Ulcer
9%
Pruritus
9%
Skin Manifestation
9%
Exanthem
9%
Mesothelioma
9%
Scalp
9%
Topical Corticosteroid
9%
Hyperhidrosis
9%
Skin Care
9%
Antimitotic Agent
9%
Irritant Dermatitis
9%
Xerosis
9%
Antibiotics
9%
Chemotherapy
9%
Treatment Outcome
9%